Silence Therapeutics (NASDAQ:SLN) Receives “Buy” Rating from Chardan Capital

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $55.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. Jefferies Financial Group began coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective for the company. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Monday. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Silence Therapeutics presently has a consensus rating of “Buy” and an average target price of $57.20.

Silence Therapeutics Stock Down 6.2 %

Shares of NASDAQ:SLN opened at $7.99 on Tuesday. Silence Therapeutics has a 52-week low of $5.81 and a 52-week high of $27.72. The stock has a market cap of $239.12 million, a P/E ratio of -5.09 and a beta of 1.05. The business has a fifty day moving average of $14.64 and a two-hundred day moving average of $17.50.

Institutional Trading of Silence Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Eventide Asset Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter valued at approximately $11,635,000. Parkman Healthcare Partners LLC boosted its position in Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after buying an additional 208,029 shares during the period. Nicholas Investment Partners LP acquired a new position in shares of Silence Therapeutics in the second quarter worth $2,859,000. Point72 Asset Management L.P. increased its position in shares of Silence Therapeutics by 1,686.6% during the second quarter. Point72 Asset Management L.P. now owns 146,500 shares of the company’s stock worth $2,784,000 after acquiring an additional 138,300 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after acquiring an additional 268,250 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.